MSC vs PRP for Knee Osteoarthritis: what the registries show
For Knee Osteoarthritis, the registry holds 124 MSC records against 163 PRP records. PRP carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | PRP |
|---|---|---|
| Registered studies | 124 | 163 |
| Recruiting now | 9 | 25 |
| Phase 3 or 4 records | 19 | 35 |
| Completed | 51 | 80 |
| Stopped early | 6 | 10 |
| Countries with sites | 30 | 36 |
| Median planned enrolment | 30 | 78 |
| First registration year | 2,008 | 2,008 |
The condition underneath the comparison
The knee is the most-studied joint in cell therapy: accessible, high-volume, with validated pain and function scales and imaging that can track cartilage. Proposed mechanisms are anti-inflammatory and chondroprotective rather than cartilage regrowth, despite marketing that regularly implies new cartilage.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
PRP: what it is
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
Maturity difference
MSC has 19 Phase 3/4 records and 51 completed studies; PRP has 35 and 80. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07542808 — An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Prod | Phase 2, Phase 3 | Recruiting | 140 | Cellcolabs Clinical SPV Limited | 2026-04-27 |
| NCT07339111 — Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Phase 3 | Recruiting | 300 | Medipost, Inc. | 2026-03-11 |
| NCT06570291 — Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | Phase 3 | Recruiting | 520 | Wuxi Cellular Biopharmaceutical Group Ltd. | 2025-02-28 |
| NCT06716281 — Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis | Phase 3 | Recruiting | 398 | Shanghai IxCell Biotechnology Co., LTD | 2024-01-05 |
| NCT05933434 — Allogenic Mesenchymal Stem Cell Intraarticular Injection for Knee Osteoarthritis Therapy | Phase 1, Phase 2 | Recruiting | 80 | Aarhus University Hospital | 2024-03-07 |
Leading PRP studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05517434 — Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA | Phase 2, Phase 3 | Recruiting | 148 | University Health Network, Toronto | 2025-01-01 |
| NCT05412381 — PRP in ACLR to Prevent PTOA | Phase 3 | Recruiting | 56 | Hospital for Special Surgery, New York | 2022-06-27 |
| NCT06451120 — Platelet Rich Plasma Injections In Young And Old Human Subjects | Phase 2 | Recruiting | 60 | University of California, San Francisco | 2024-06-01 |
| NCT06163573 — Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. | Phase 2 | Recruiting | 75 | University Hospital, Basel, Switzerland | 2024-06-06 |
| NCT03491761 — Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis | Phase 2 | Recruiting | 100 | Endeavor Health | 2018-06-13 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than PRP for Knee Osteoarthritis?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 124 vs 163 registered records (2026-08-29).
Which has more late-stage research for Knee Osteoarthritis?
MSC: 19 Phase 3/4 records. PRP: 35.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.